Merck & Co. Inc. (MRK) Q1 2026 (USD): Adj. EPS -1.28 (exp. -1.47), Revenue 16.29bln (exp. 15.85bln), Keytruda sales 8bln (exp. 7.62bln)
- Q1 GAAP and non-GAAP loss per share include USD 3.62/shr charge for acquisition of Cidara.
Guidance:
- FY adj. EPS 5.04-5.16 (exp. 5.10).
- FY sales 65.8-67bln (exp. 66.6bln).
Context
Merck & Co. reported Q1 results that beat expectations on both adjusted EPS and revenue, with particularly strong sales from Keytruda, which exceeded estimates significantly. This performance could signal robust demand in the pharmaceutical sector, potentially bolstering confidence in the stock’s outlook and influencing peers in the industry, despite the present GAAP losses due to an acquisition charge.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#GERMANY#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#MERCK & CO INC#MRK.US#MERCK KGAA#IMPORTANT#FOREX#EQUITIES#METALS#EU SESSION#PHARMACEUTICALS#METALS & MINING#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#DAX 40 INDEX#MRK#DXY#US EQUITIES